Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Opportunity In China, But Regulatory Pathway Still Missing - Biosimilars Asia Conference

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Biosimilars makers foresee a huge opportunity in the emerging pharma market of China, which is expected to grow by 22-25% as of 2014, speakers from the IBC Biosimilars Asia Conference in Shanghai said May 24
Advertisement

Related Content

Increased Biomarker Testing Could Boost Oncology Market In China
After Brazil Onto China? Amgen Unveils Emerging Market Strategy
After Brazil Onto China? Amgen Unveils Emerging Market Strategy
Sanofi-Aventis Scans Asian Firms For Alliances In Biosimilar Development And Marketing
Biocon Chairperson Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 2 of 2)
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
Advertisement
UsernamePublicRestriction

Register

SC078037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel